19 June 2013
Keywords: strong, ph, iii, data, titan, opioid, addiction
Article | 04 August 2008
The USA's Titan Pharmaceuticals has reported positive, statistically-significant results from a Phase III trial of Probuphine,
a subcutaneous implant designed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 December 2008
© 2013 thepharmaletter.com